(Q51368060)

English

Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety.

scientific article published on 13 January 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22246377

Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety. (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22246377

0 references

0 references

congestive heart failure

1 reference

based on heuristic

inferred from title

author name string

D Nathanson

1

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22246377

B Ullman

2

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22246377

U Löfström

3

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22246377

A Hedman

4

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22246377

M Frick

5

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22246377

A Sjöholm

6

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22246377

T Nyström

7

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22246377

publication date

13 January 2012

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22246377

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22246377

55

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22246377

4

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22246377

926-935

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22246377

The potential beneficial role of glucagon-like peptide-1 in endothelial dysfunction and heart failure associated with insulin resistance

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Mechanical properties of primary cilia regulate the response to fluid flow

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Gq/G13 signaling by ET-1 in smooth muscle: MYPT1 phosphorylation via ETA and CPI-17 dephosphorylation via ETB.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Cardiac function in mice lacking the glucagon-like peptide-1 receptor

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Cardiac metabolism as a target for the treatment of heart failure

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Mesenteric vasoconstriction and hindquarters vasodilatation accompany the pressor actions of exendin-4 in conscious rats

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Endothelial dysfunction induced by triglycerides is not restored by exenatide in rat conduit arteries ex vivo.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Autonomic nervous system-dependent and -independent cardiovascular effects of exendin-4 infusion in conscious rats

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

The adrenergic-fatty acid load in heart failure

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Diastolic Stiffness of the Failing Diabetic Heart

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/22246377

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure

1 reference

https://pubmed.ncbi.nlm.nih.gov/22246377

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure

1 reference

https://pubmed.ncbi.nlm.nih.gov/22246377

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators

1 reference

https://pubmed.ncbi.nlm.nih.gov/22246377

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22246377

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart

1 reference

https://pubmed.ncbi.nlm.nih.gov/22246377

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction

1 reference

https://pubmed.ncbi.nlm.nih.gov/22246377

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sex and type 2 diabetes: obesity-independent effects on left ventricular substrate metabolism and relaxation in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/22246377

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor

1 reference

https://pubmed.ncbi.nlm.nih.gov/22246377

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22246377

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interactions of exendin-(9–39) with the effects of glucagon-like peptide-1-(7–36) amide and of exendin-4 on arterial blood pressure and heart rate in rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/22246377

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22246377

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting

1 reference

https://pubmed.ncbi.nlm.nih.gov/22246377

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers

1 reference

https://pubmed.ncbi.nlm.nih.gov/22246377

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00125-011-2440-X

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22246377

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22246377

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51368060&oldid=2210834423"